• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

p97 和组蛋白去乙酰化酶 6 在介导套细胞淋巴瘤细胞 DNA 修复中的功能协同作用。

Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells.

机构信息

Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Kanas City, KS, USA.

Department of Cancer Biology, The University of Kansas Cancer Center, Kanas City, KS, USA.

出版信息

Leukemia. 2019 Jul;33(7):1675-1686. doi: 10.1038/s41375-018-0355-y. Epub 2019 Jan 21.

DOI:10.1038/s41375-018-0355-y
PMID:30664664
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6730676/
Abstract

p97 is an ATPase that works in concert with histone deacetylase 6 (HDAC6), to facilitate the degradation of misfolded proteins by autophagosomes. p97 has also been implicated in DNA repair and maintaining genomic stability. In this study, we determined the effect of combined inhibition of p97 and HDAC6 activities in mantle cell lymphoma (MCL) cells. We report that treatment with p97 inhibitors induces dose-dependent apoptosis in MCL cells. The p97 inhibitor CB-5083 induces ER stress markers GRP78 and CHOP and results in the accumulation of polyubiquitylated proteins. Co-treatment with CB-5083 and the HDAC6 inhibitor ACY-1215 result in marked downregulation of CDK4, Cyclin D1, and BRCA1 levels without inhibiting autophagic flux. Consequently, treatment with CB-5083 accentuates DNA damage in response to treatment with ACY-1215 resulting in enhanced accumulation of H2AX-γ and synergistic apoptosis. Furthermore, ATM loss severely impairs phosphorylation of 53BP1 following co-treatment with CB-5083 and ACY-1215 in response to gamma irradiation. Finally, co-treatment CB-5083 and ACY-1215 results in reduced tumor volumes and improves survival in Z138C and Jeko-1 xenografts in NSG mice. These observations suggest that combined inhibition of p97 and HDAC6 abrogates resolution of proteotoxic stress and impairs DNA repair mechanisms in MCL cells.

摘要

p97 是一种 ATP 酶,与组蛋白去乙酰化酶 6(HDAC6)协同作用,促进自噬体对错误折叠蛋白质的降解。p97 还与 DNA 修复和维持基因组稳定性有关。在这项研究中,我们确定了联合抑制 p97 和 HDAC6 活性对套细胞淋巴瘤(MCL)细胞的影响。我们报告说,p97 抑制剂的治疗在 MCL 细胞中诱导剂量依赖性凋亡。p97 抑制剂 CB-5083 诱导内质网应激标志物 GRP78 和 CHOP,并导致多泛素化蛋白的积累。与 CB-5083 和 HDAC6 抑制剂 ACY-1215 共同治疗导致 CDK4、Cyclin D1 和 BRCA1 水平明显下调,而不抑制自噬通量。因此,CB-5083 的治疗加重了对 ACY-1215 治疗的 DNA 损伤,导致 H2AX-γ 的积累增加和协同凋亡。此外,ATM 缺失严重损害了 CB-5083 和 ACY-1215 共同处理后对 γ 辐射的反应中 53BP1 的磷酸化。最后,CB-5083 和 ACY-1215 的联合治疗导致 Z138C 和 Jeko-1 异种移植瘤在 NSG 小鼠中的肿瘤体积减少和存活率提高。这些观察结果表明,联合抑制 p97 和 HDAC6 可消除蛋白毒性应激的解决,并损害 MCL 细胞中的 DNA 修复机制。

相似文献

1
Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells.p97 和组蛋白去乙酰化酶 6 在介导套细胞淋巴瘤细胞 DNA 修复中的功能协同作用。
Leukemia. 2019 Jul;33(7):1675-1686. doi: 10.1038/s41375-018-0355-y. Epub 2019 Jan 21.
2
Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.联合表观遗传学疗法对人套细胞淋巴瘤细胞的优越疗效。
Clin Cancer Res. 2012 Nov 15;18(22):6227-38. doi: 10.1158/1078-0432.CCR-12-0873. Epub 2012 Aug 29.
3
ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.ACY-1215,一种组蛋白去乙酰化酶 6 抑制剂,可抑制黑色素瘤中的癌细胞生长。
J Biol Regul Homeost Agents. 2018 Jul-Aug;32(4):851-858.
4
Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.联合使用泛组蛋白去乙酰化酶抑制剂和自噬抑制剂可显著增强对三阴性人乳腺癌细胞的疗效。
Mol Cancer Ther. 2012 Apr;11(4):973-83. doi: 10.1158/1535-7163.MCT-11-0979. Epub 2012 Feb 24.
5
The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.组蛋白去乙酰化酶 6 选择性抑制剂对非霍奇金淋巴瘤有效,并与伊布替尼在滤泡性淋巴瘤中协同作用。
Mol Carcinog. 2019 Jun;58(6):944-956. doi: 10.1002/mc.22983. Epub 2019 Feb 27.
6
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.基于BET蛋白拮抗剂的联合用药在对依鲁替尼敏感或耐药的套细胞淋巴瘤细胞中的协同活性。
Blood. 2015 Sep 24;126(13):1565-74. doi: 10.1182/blood-2015-04-639542. Epub 2015 Aug 7.
7
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.一种选择性 HDAC6 抑制剂 ACY-1215 与硼替佐米联合治疗多发性骨髓瘤的临床前活性、药效学和药代动力学特性。
Blood. 2012 Mar 15;119(11):2579-89. doi: 10.1182/blood-2011-10-387365. Epub 2012 Jan 19.
8
A novel HDAC6 inhibitor Tubastatin A: Controls HDAC6-p97/VCP-mediated ubiquitination-autophagy turnover and reverses Temozolomide-induced ER stress-tolerance in GBM cells.一种新型组蛋白去乙酰化酶6(HDAC6)抑制剂Tubastatin A:控制HDAC6-p97/缬酪肽蛋白(VCP)介导的泛素化-自噬周转,并逆转替莫唑胺诱导的胶质母细胞瘤(GBM)细胞内质网应激耐受性。
Cancer Lett. 2017 Apr 10;391:89-99. doi: 10.1016/j.canlet.2017.01.025. Epub 2017 Jan 26.
9
Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.选择性组蛋白去乙酰化酶6(HDAC6)抑制剂ACY-1215与硼替佐米对蛋白质降解途径的双重靶向作用在淋巴瘤中具有协同效应。
Clin Cancer Res. 2015 Oct 15;21(20):4663-75. doi: 10.1158/1078-0432.CCR-14-3068. Epub 2015 Jun 26.
10
Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.HDAC6 激活 MET 信号为弥漫性大 B 细胞淋巴瘤的新型 ricolinostat 和克唑替尼联合治疗策略提供了依据。
J Pathol. 2018 Oct;246(2):141-153. doi: 10.1002/path.5108. Epub 2018 Aug 20.

引用本文的文献

1
Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer.吡咯替尼靶向表皮生长因子受体/葡萄糖调节蛋白78介导的高表皮生长因子受体基因拷贝数胃癌细胞凋亡。
J Exp Clin Cancer Res. 2025 Aug 19;44(1):245. doi: 10.1186/s13046-025-03485-6.
2
Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases?在血液肿瘤疾病中,HSP70 仍然可以作为治疗靶点吗?
Biomolecules. 2023 Mar 28;13(4):604. doi: 10.3390/biom13040604.
3
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.

本文引用的文献

1
Cdc48/p97 segregase is modulated by cyclin-dependent kinase to determine cyclin fate during G1 progression.Cdc48/p97 分离酶通过细胞周期蛋白依赖性激酶调节来决定 G1 期进展过程中细胞周期蛋白的命运。
EMBO J. 2018 Aug 15;37(16). doi: 10.15252/embj.201798724. Epub 2018 Jun 27.
2
53BP1 Mediates ATR-Chk1 Signaling and Protects Replication Forks under Conditions of Replication Stress.53BP1 介导 ATR-Chk1 信号通路并在复制压力条件下保护复制叉。
Mol Cell Biol. 2018 Mar 29;38(8). doi: 10.1128/MCB.00472-17. Print 2018 Apr 15.
3
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.
造血过程中的表观遗传调控及其在血液系统恶性肿瘤靶向治疗中的意义。
Signal Transduct Target Ther. 2023 Feb 17;8(1):71. doi: 10.1038/s41392-023-01342-6.
4
VCP inhibition induces an unfolded protein response and apoptosis in human acute myeloid leukemia cells.VCP 抑制剂诱导人急性髓系白血病细胞发生未折叠蛋白反应和细胞凋亡。
PLoS One. 2022 Apr 6;17(4):e0266478. doi: 10.1371/journal.pone.0266478. eCollection 2022.
5
Valosin-Containing Protein (VCP)/p97: A Prognostic Biomarker and Therapeutic Target in Cancer.包含缬氨酸蛋白(VCP)/ p97:癌症的预后生物标志物和治疗靶点。
Int J Mol Sci. 2021 Sep 21;22(18):10177. doi: 10.3390/ijms221810177.
6
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition).自噬监测分析方法使用和解释的指南(第 4 版)。
Autophagy. 2021 Jan;17(1):1-382. doi: 10.1080/15548627.2020.1797280. Epub 2021 Feb 8.
7
Actin-granule formation is an additional step in cardiac myofibroblast differentiation.肌动蛋白颗粒形成是心肌成纤维细胞分化过程中的一个额外步骤。
Ann Transl Med. 2021 Jan;9(2):165. doi: 10.21037/atm-20-8231.
8
Delicaflavone Reverses Cisplatin Resistance via Endoplasmic Reticulum Stress Signaling Pathway in Non-Small Cell Lung Cancer Cells.地锦草黄酮通过内质网应激信号通路逆转非小细胞肺癌细胞的顺铂耐药性。
Onco Targets Ther. 2020 Oct 13;13:10315-10322. doi: 10.2147/OTT.S255586. eCollection 2020.
9
Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies.组蛋白去乙酰化酶6作为B细胞相关血液系统恶性肿瘤的治疗靶点
Front Pharmacol. 2020 Jun 26;11:971. doi: 10.3389/fphar.2020.00971. eCollection 2020.
P97 抑制剂 CB-5083 是多发性骨髓瘤模型中蛋白质动态平衡的独特破坏者。
Mol Cancer Ther. 2017 Nov;16(11):2375-2386. doi: 10.1158/1535-7163.MCT-17-0233. Epub 2017 Sep 6.
4
The role of ubiquitin-dependent segregase p97 (VCP or Cdc48) in chromatin dynamics after DNA double strand breaks.泛素依赖性分离酶p97(VCP或Cdc48)在DNA双链断裂后染色质动力学中的作用。
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 5;372(1731). doi: 10.1098/rstb.2016.0282.
5
Proteasome inhibitors in cancer therapy.蛋白酶体抑制剂在癌症治疗中的应用。
Nat Rev Clin Oncol. 2017 Jul;14(7):417-433. doi: 10.1038/nrclinonc.2016.206. Epub 2017 Jan 24.
6
The molecular pathogenesis of mantle cell lymphoma.套细胞淋巴瘤的分子发病机制。
Leuk Lymphoma. 2017 Jul;58(7):1530-1537. doi: 10.1080/10428194.2016.1248965. Epub 2016 Nov 28.
7
VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal.VCP抑制剂可诱导内质网应激,导致细胞周期停滞,触发半胱天冬酶介导的细胞死亡,并与Salubrinal联合使用时协同杀死卵巢癌细胞。
Mol Oncol. 2016 Dec;10(10):1559-1574. doi: 10.1016/j.molonc.2016.09.005. Epub 2016 Sep 28.
8
VCP/p97 Extracts Sterically Trapped Ku70/80 Rings from DNA in Double-Strand Break Repair.VCP/p97在双链断裂修复过程中从DNA中提取空间捕获的Ku70/80环。
Mol Cell. 2016 Oct 6;64(1):189-198. doi: 10.1016/j.molcel.2016.08.037.
9
Targeting p97 to Disrupt Protein Homeostasis in Cancer.靶向p97以破坏癌症中的蛋白质稳态。
Front Oncol. 2016 Aug 3;6:181. doi: 10.3389/fonc.2016.00181. eCollection 2016.
10
Gene mutations and actionable genetic lesions in mantle cell lymphoma.套细胞淋巴瘤中的基因突变及可靶向治疗的基因损伤
Oncotarget. 2016 Sep 6;7(36):58638-58648. doi: 10.18632/oncotarget.10716.